Phase 2 trial of LTI-03 for the treatment of Idiopathic-pulmonary-fibrosis
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs LTI 03 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- 16 Jan 2025 New trial record
- 10 Jan 2025 According to Rein Therapeutics media release, Aileron Therapeutics announces rebranding to Rein Therapeutics
- 10 Jan 2025 According to Rein Therapeutics media release, this phase 2 trial of LTI-03 for the treatment of IPF is anticipated to be initiated in the first half of this year.